



Short-Term Clinical Effects of Standardized *Syzygium polyanthum* (Bay Leaf) Tea Infusion on Serum Uric Acid Modulation in Hyperuricemia: A Pilot Trial in Primary Care

Andi Asda Astiah^{1*}, Isramilda¹, Deby Febriyanti²

¹Faculty of Medicine, Universitas Batam, Batam, Indonesia

²Student, Faculty of Medicine, Universitas Batam, Batam, Indonesia

ARTICLE INFO

Keywords:

Hyperuricemia
Phytotherapy
Primary health care
Syzygium polyanthum
Xanthine oxidase

***Corresponding author:**

Andi Asda Astiah

E-mail address:

andiasda@uniubatam.ac.id

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/cmej.v7i1.873>

ABSTRACT

Hyperuricemia management relies heavily on synthetic xanthine oxidase inhibitors, which possess adverse effect risks. This pilot trial evaluates the short-term clinical effects of a standardized *Syzygium polyanthum* (Indonesian bay leaf) tea infusion on serum uric acid levels in a primary care setting, standardizing conventional preparation methods. A quasi-experimental, pre- and post-test controlled pilot trial was conducted at a community health center on Sumatra Island, Indonesia. Twenty-four adults with hyperuricemia were purposively assigned (alternating days of presentation) to an intervention group (n=12) or a control group (n=12). The intervention comprised 2.0 grams of standardized *S. polyanthum* tea infused at 80 degrees Celsius for 1 to 3 minutes, consumed twice daily for seven days. Both groups underwent monitored dietary purine restriction. Serum uric acid was evaluated via capillary analysis. The intervention cohort exhibited a statistically significant reduction in median serum uric acid from 8.1 mg/dL (Interquartile Range [IQR]: 7.4–8.9) to 6.9 mg/dL (IQR: 6.2–7.5) (p=0.034). The control group showed no significant alteration (median 8.0 mg/dL to 7.9 mg/dL; p=0.299). Intervention compliance was 95.4%, with no adverse gastrointestinal events reported. In conclusion, standardized *S. polyanthum* tea infusion significantly reduces serum uric acid over seven days, presenting a culturally syntonetic and safe complementary intervention for primary healthcare frameworks, though extended treatment may be required to reach optimal clinical targets below 6.0 mg/dL.

1. Introduction

Hyperuricemia represents a profoundly complex, progressive metabolic disorder that is fundamentally characterized by the pathological elevation and systemic accumulation of serum uric acid concentrations. This physiological imbalance does not manifest in biological isolation; rather, it arises from a persistent dysregulation originating either from the systemic endogenous overproduction of uric acid, the critical impairment of renal excretion pathways for this metabolite, or a pathological confluence of both fundamental homeostatic mechanisms. To fully

comprehend the expansive systemic burden of this condition, it is absolutely necessary to examine the intricate biochemical origins of uric acid. As the terminal metabolic byproduct of purine catabolism in humans—a species that inherently lacks the functional uricase enzyme required to further degrade uric acid into the highly water-soluble compound allantoin—uric acid accumulation is a continuous and ubiquitous biological risk. The synthesis of this compound is driven through a highly sequential, tightly regulated oxidative cascade heavily facilitated by the hepatic enzyme xanthine oxidase. This specific

molybdenum-dependent metalloflavoprotein orchestrates the sequential hydroxylation of hypoxanthine into xanthine, and the subsequent, highly irreversible conversion of xanthine directly into uric acid.¹

Clinical diagnostic thresholds, which are structurally guided by the strict physiological solubility limits of urate within the extracellular fluid, traditionally define hyperuricemia as sustained serum uric acid levels surpassing 7.0 mg/dL in men and 6.0 mg/dL in women. When these precise physiological saturation points are consistently exceeded, the systemic hematological environment becomes highly conducive to the spontaneous nucleation and precipitation of monosodium urate crystals. Historically, the broader medical community primarily viewed hyperuricemia through the somewhat narrow and highly specific lens of clinical rheumatology, recognizing it chiefly as the foundational biochemical precursor to gouty arthritis and the localized, painful deposition of crystals within articular joint spaces and surrounding soft tissues. However, an overwhelming surge of contemporary epidemiological data and advanced pathophysiological evidence has radically expanded and redefined this classical paradigm. Sustained hyperuricemia is now aggressively and universally recognized as an independent, highly potent risk factor for a remarkably broad spectrum of severe systemic complications.² Elevated serum urate operates as a direct and aggressive mediator of endothelial dysfunction. It achieves this cellular damage by rapidly depleting the availability of endothelial nitric oxide—a crucial vasodilator—while simultaneously and dramatically amplifying the localized intracellular production of reactive oxygen species. This rapid propagation of systemic oxidative stress invariably triggers aggressive inflammatory cytokine cascades, tightly linking chronic hyperuricemia to accelerated renal function degradation, the insidious onset of essential hypertension, and the rapid progression of severe cardiovascular morbidities, ultimately escalating the global public health burden to unprecedented levels.

The contemporary pharmacological paradigm dedicated to managing chronic hyperuricemia predominantly relies on the targeted, lifelong administration of synthetic xanthine oxidase inhibitors. Within standard clinical practice, this therapeutic strategy is heavily dominated by two primary, distinct pharmacological agents: allopurinol, which acts as a purine analogue, and febuxostat, which functions as a non-purine selective inhibitor.³ By effectively occupying the catalytic cleft of the xanthine oxidase enzyme, these synthetic agents successfully and rapidly suppress endogenous uric acid synthesis at the hepatic level, subsequently modulating downstream systemic inflammatory cascades and significantly reducing the overall circulating urate burden. Despite their deeply documented, undeniable clinical efficacy and their foundational, undisputed role in all current international management guidelines, the long-term, ubiquitous utilization of these powerful synthetic inhibitors is frequently and severely constrained by a complex array of pressing clinical and toxicological concerns.

Allopurinol administration is notoriously associated with a wide and unpredictable spectrum of adverse cutaneous reactions. These physiological responses can range from relatively mild maculopapular dermatological eruptions to acute, life-threatening dermatological emergencies, most notably Stevens-Johnson syndrome and toxic epidermal necrolysis.⁴ The persistent risk of allopurinol hypersensitivity syndrome presents a constant, severe clinical challenge. Because allopurinol and its active circulating metabolite, oxypurinol, rely almost entirely on extensive renal clearance pathways, its administration strictly mandates highly stringent dose adjustments and continuous, costly monitoring in patients presenting with pre-existing renal impairment. This creates a highly paradoxical clinical dilemma, given that hyperuricemia itself is a known primary driver of progressive chronic kidney disease. Febuxostat, while intentionally engineered to offer an alternative metabolic elimination pathway that relies

far more heavily on hepatic glucuronidation rather than renal clearance, has been subjected to intense, ongoing clinical scrutiny regarding its potential to induce marked hepatotoxicity and a highly debated increased risk of adverse cardiovascular and thromboembolic events. The cumulative renal and hepatic physiological burden associated with the required lifelong administration of these potent synthetic compounds invariably leads to exceptionally high rates of patient non-compliance, therapeutic fatigue, and ultimate treatment failure. Consequently, this prevailing, deeply entrenched clinical dilemma has rapidly accelerated a global, rigorous scientific investigation into alternative, plant-derived therapeutic agents. The overarching scientific objective is to carefully identify and isolate botanical compounds that can confidently offer comparable biochemical efficacy in suppressing systemic uric acid production while inherently maintaining vastly superior, sustainable safety profiles that are entirely suitable for long-term administration without imposing any secondary iatrogenic organ burden.

Within this intense, highly focused global search for viable, safe botanical alternatives, the deliberate integration of indigenous knowledge—often specifically referred to as *Kearifan Lokal* in the Indonesian context—has proven to be an unequivocally invaluable scientific resource. Traditional medicinal systems have long utilized endemic flora to empirically manage complex metabolic ailments, providing a rich, multi-generational observational foundation for rigorous modern pharmacological validation.⁵ *Syzygium polyanthum*, commonly known throughout the archipelago as the Indonesian bay leaf, occupies a highly prominent, deeply respected, and culturally syntonious position within traditional Southeast Asian medicinal systems. Historically utilized simultaneously as a foundational culinary spice and a potent empirical therapeutic agent, this indigenous plant is deeply embedded in the daily cultural and nutritional fabric of the region. Comprehensive phytochemical profiling, utilizing highly advanced

high-performance liquid chromatography and mass spectrometry techniques, indicates that the mature leaves of *S. polyanthum* are densely populated with a vast, highly complex array of bioactive molecular constituents.⁶ The most critical among these active agents are abundant polyphenolic compounds, specifically diverse flavonoids and high-molecular-weight hydrolyzable tannins, alongside highly significant concentrations of specific triterpenoid saponins and highly volatile essential oils, predominantly including eugenol, citral, and various sesquiterpenes.

Advanced in vitro pharmacological fractionations and subsequent molecular docking studies have clearly elucidated the specific, targeted molecular pharmacodynamics of these remarkable botanical constituents. It is now completely understood that the flavonoid and tannin components execute a highly potent, direct competitive inhibition of the targeted xanthine oxidase enzymatic activity.⁷ Structurally, the specific planar nature of the varied flavonoid aglycones found abundantly within *S. polyanthum* allows them to perfectly and seamlessly mimic the molecular purine ring of the enzyme's natural biological substrates, such as hypoxanthine. These bioactive molecules physically infiltrate the highly hydrophobic catalytic cleft of the xanthine oxidase enzyme, directly coordinating with the active molybdenum-pterin transition center and effectively blocking the binding and subsequent oxidation of natural circulating purines. By directly and competitively impeding this critical terminal oxidation process, the botanical extract significantly and rapidly curtails the endogenous hepatic synthesis of uric acid. Concurrently, numerous preclinical animal models utilizing precisely calibrated potassium oxonate administrations to induce acute, sustained hyperuricemia have provided incredibly robust in vivo physiological validation. These critical studies have not only explicitly demonstrated the botanical extract's unparalleled capacity to significantly depress systemic serum uric acid levels back to normalized physiological baselines, but they have also

prominently highlighted its secondary ability to actively mitigate localized hepatic and renal tissue inflammation through highly potent, intrinsic antioxidant signaling pathways. Furthermore, the concurrent presence of specific, measurable saponins and volatile essential oils introduces a highly credible, theorized dual-action biological mechanism; these secondary plant metabolites are biochemically known to exert distinct, localized diuretic properties, potentially significantly enhancing glomerular filtration rates within the nephron and heavily expediting the physical renal clearance and excretion of the remaining existing systemic urate burden.⁸

Despite this remarkably robust, scientifically verified preclinical substantiation and incredibly clear, targeted biochemical rationale, highly structured translational human clinical trials evaluating the true physiological effects of *S. polyanthum* remain lamentably sparse, overwhelmingly fragmented, and frequently undermined by profound, structural methodological flaws.⁹ A highly critical, systemic limitation that remains overwhelmingly pervasive throughout the entirety of the existing ethnopharmacological literature is the prevailing, completely uncritical reliance on conventional, highly unstandardized aqueous boiling methods for raw botanical extract preparation. This deeply archaic approach to applied phytotherapy routinely relies on instructing participating patients to arbitrarily boil an unspecified, non-standardized handful of raw leaves in entirely open vessels for an entirely unspecified, fluctuating duration. This severely flawed methodology instantly introduces severe, entirely uncontrollable variability in the final molecular phytochemical yield.

Subjecting incredibly delicate botanical matrices to prolonged, sustained, high-temperature boiling well beyond the critical ninety-degree Celsius threshold frequently and predictably causes the rapid, irreversible thermal degradation of highly thermolabile active compounds. This rapid molecular destruction primarily impacts the very crucial flavonoid glycosides that are directly responsible for executing the desired xanthine oxidase inhibition. Additionally, the open-

boiling process allows for the incredibly rapid, unchecked atmospheric volatilization of the lighter essential oils, specifically compounds like eugenol, effectively stripping the final preparation of its highly valuable adjunctive diuretic properties. Furthermore, the immense variations in initial raw leaf moisture content, exact boiling duration, initial water volume, and highly variable thermal heating intensity mean that the final concentration of active therapeutic metabolites actually administered to the patient fluctuates wildly and unpredictably from one individual dose to the absolutely next. This profound, undeniable lack of rigorous standardization severely and irrevocably compromises basic dosage reliability, entirely negating any real possibility of achieving longitudinal therapeutic consistency or predictable biochemical modulation. It is fundamentally impossible to definitively or scientifically evaluate the genuine clinical efficacy of any botanical intervention when the primary active pharmaceutical ingredient is delivered to the systemic circulation in highly erratic, entirely unquantifiable concentrations. For traditional empirical medicine to successfully and permanently transition into modern, highly regulated, evidence-based primary care frameworks, these botanical interventions must be rigorously, mathematically standardized to guarantee that every single administered dose reliably provides a highly consistent, therapeutically active molecular yield.¹⁰

To urgently and comprehensively address this incredibly critical methodological chasm within current phytopharmacological research, this specific clinical study explicitly presents a highly refined, strictly regulated translational approach to applied botanical medicine. This pilot study aims to rigorously and clinically evaluate the short-term biochemical and therapeutic effects of a precisely formulated, highly standardized *S. polyanthum* tea bag formulation in actively modulating systemic serum uric acid levels among an adult cohort formally diagnosed with chronic hyperuricemia. Furthermore, to root this vital research firmly and contextually in its true epidemiological and cultural environment, the entire

clinical trial is purposefully and strategically conducted within a dedicated, highly integrated primary care setting specifically located on Sumatra Island, Indonesia. The overarching novelty of this particular research lies squarely and undeniably in its rigorous, highly structured translational clinical methodology: this study decisively bridges the vast chasm between theoretical basic laboratory science and highly practical clinical application by successfully converting firmly established, proven *in vitro* phytochemical mechanisms into a highly standardized, strictly parameter-controlled clinical intervention. By strictly defining and actively controlling the exact botanical mass, the precise leaf particle size, the specific optimal water temperature, and the highly exact aqueous extraction kinetics, this methodology completely eliminates the profound inconsistencies inherent in traditional, unregulated boiling practices. In doing so, it provides a culturally acceptable, easily administrable, highly cost-effective, and scientifically validated therapeutic clinical protocol that is perfectly optimized for broad, immediate deployment within foundational primary healthcare frameworks, ultimately offering a highly innovative, incredibly safe new paradigm for the long-term management of hyperuricemia in susceptible populations.

2. Methods

Ethical consideration

This pilot clinical trial was conducted in strict adherence to the ethical principles outlined in the Declaration of Helsinki for medical research involving human subjects. Prior to study initiation, the comprehensive research protocol, encompassing all intervention procedures and data collection methodologies, received formal ethical clearance from the Faculty of Medicine, Universitas Batam, Indonesia. All twenty-four prospective participants received culturally appropriate written and verbal explanations regarding the study objectives, the standardized botanical intervention, potential risks, and their fundamental rights. Subsequently, voluntary written

informed consent was obtained from every individual prior to formal enrollment. To ensure absolute confidentiality, all clinical and biochemical data were fully anonymized, securely stored, and accessed solely for designated research purposes. Furthermore, participants retained the unassailable right to withdraw from the trial at any juncture without experiencing prejudice or any disruption to their standard primary healthcare services at the community health center.

Study design and setting

This research employed a rigorously controlled quasi-experimental design, specifically utilizing a pre-test and post-test control group framework. Recognizing the limitations of quasi-experimental structures, this study is explicitly designated as a pilot or proof-of-concept trial to establish initial clinical parameters for future expansive research. The study was executed at a localized Community Health Center situated on Sumatra Island, Indonesia. This specific primary care setting was strategically selected due to the high regional prevalence of metabolic non-communicable diseases and the community's heavy reliance on integrated, holistic health services and traditional medicinal practices.

Population and sampling

The reference population encompassed all adult patients formally diagnosed with hyperuricemia residing within the catchment area of the designated primary care center. A sample size of 24 participants was determined using a priori power analysis for a Wilcoxon-Mann-Whitney test, assuming an alpha error probability of 0.05, a power of 0.80, and a conservative moderate effect size based on preliminary botanical data. To mitigate selection bias inherent in non-randomized designs, a structured purposive assignment protocol was implemented. Participants presenting to the clinic on Mondays and Wednesdays who met the criteria were assigned to the intervention group (n=12), while those presenting on Tuesdays and Thursdays were assigned to the control group (n=12).

Inclusion criteria required participants to be adults (aged 30 to 65 years) with confirmed hyperuricemia (serum uric acid >6.0 mg/dL for females; >7.0 mg/dL for males), abstaining from synthetic urate-lowering pharmacotherapy during the study period, and providing written informed consent. Exclusion criteria strictly omitted individuals with a known hypersensitivity to Myrtaceae species, pregnant or lactating women, and patients presenting with severe hepatic conditions or advanced chronic kidney disease that fundamentally alters uric acid metabolism.

Intervention Protocol and Phytochemical Rationale

The therapeutic formulation consisted of commercially prepared, highly standardized tea bags containing exactly 2.0 grams of pulverized *Syzygium polyanthum* leaves. Participants in the intervention cohort were instructed to submerge one tea bag in 200 to 300 mL of heated water, strictly maintained at approximately 80 degrees Celsius, for a duration of 1 to 3 minutes. This specific extraction kinetic protocol was chosen based on established phytochemical principles. Water temperatures exceeding 90 degrees Celsius induce rapid thermal degradation of thermolabile flavonoid glycosides. Conversely, the 80-degree threshold optimally dissolves planar flavonoid aglycones and low-molecular-weight hydrolyzable tannins into the aqueous matrix. The restricted steeping duration of 1 to 3 minutes is engineered to prevent the total volatilization of critical essential oils, specifically eugenol, which possess adjunctive diuretic properties. This infusion was administered twice daily (morning and evening) for seven consecutive days.

Dietary control and monitoring

To isolate the pharmacological effects of the intervention, rigorous dietary control was implemented. Both cohorts received identical, structured clinical counseling mandating the strict limitation of purine-dense foods (organ meats, certain seafoods, specific legumes) and total abstinence from alcohol. Crucially, to prevent baseline purine intake from acting as an uncontrolled confounding variable, dietary adherence was actively monitored. Trained

nutritionists conducted structured 24-hour dietary recalls via telephone on Day 3 and Day 6 of the trial. Purine loads were calculated to ensure uniform dietary compliance across both the intervention and control arms.

Clinical measurements and safety tracking

The primary clinical endpoint, serum uric acid concentration, was quantified using an Easy Touch GCU point-of-care capillary blood monitoring system. While acknowledging that capillary testing inherently possesses a higher coefficient of variation compared to standard venous serum laboratory analysis, this modality was selected due to the strictly resource-limited setting of the rural primary care center. To ensure maximal reliability, all measurements were executed by a single trained clinical technician using the same calibrated device under standardized environmental conditions at Day 0 (baseline pre-test) and Day 8 (post-test). Safety and tolerability were tracked continuously; participants were required to record any adverse gastrointestinal events, headaches, or dizziness in a daily logbook, which was reviewed at the conclusion of the trial.

Statistical analysis

Quantitative data analysis was performed utilizing IBM SPSS Statistics software. Descriptive statistics defined the demographic and baseline clinical architecture of the cohort. The Shapiro-Wilk test was utilized to evaluate data distribution normality. Results indicated a significantly non-normal distribution of the primary continuous variables, including serum uric acid levels ($p < 0.05$). Consequently, non-parametric statistical pathways were adopted. All continuous variables are reported strictly as Medians accompanied by Interquartile Ranges (IQR). The Wilcoxon Signed-Rank test was applied to assess intra-group variances (pre- versus post-intervention). The Mann-Whitney U test was executed to determine the statistical significance of the inter-group differential in serum uric acid reduction.

The alpha level for statistical significance was established a priori at 0.05.

3. Results

The study successfully retained all 24 initial participants through the final clinical evaluation, representing a zero percent attrition rate. The cohort demonstrated a predominance of female participants

(62.5%) and a high concentration of individuals aged between 31 and 45 years. Baseline anthropometric and hemodynamic parameters, including Body Mass Index and blood pressure, were uniformly distributed between the intervention and control arms prior to treatment initiation, indicating successful purposive assignment balancing.


Table 1. Demographic and Expanded Baseline Clinical Characteristics of the Study Cohort

PARAMETER	CATEGORY / METRIC	TOTAL FREQUENCY (N=24)	PERCENTAGE / MEDIAN (IQR)
DEMOGRAPHIC VARIABLES			
Age	31–45 years	12	50.0%
	46–60 years	9	37.5%
	>60 years	3	12.5%
Sex	Male	9	37.5%
	Female	15	62.5%
CLINICAL BASELINES			
Body Mass Index	Continuous (kg/m ²)	24	26.5 (24.1 – 28.8)
Systolic Blood Pressure	Continuous (mmHg)	24	130 (120 – 138)
Diastolic Blood Pressure	Continuous (mmHg)	24	82 (78 – 86)

Analysis of the 24-hour dietary recalls conducted on Day 3 and Day 6 confirmed that both the intervention and control groups successfully maintained equivalent, low-purine dietary profiles, effectively neutralizing diet as a confounding variable (Figure 1). Furthermore, intervention compliance was exceptional; based on returned tea bag counts,

adherence to the twice-daily protocol was 95.4%. Regarding safety, a review of the daily participant logbooks revealed zero reported adverse events. There were no instances of gastrointestinal distress, nausea, or systemic hypersensitivity, underscoring the high acute tolerability of the standardized botanical formulation.

Dietary Adherence and Intervention Safety Profiles



Notes: Visualization of clinical adherence and safety outcomes for the total cohort (n=24). Compliance percentage (95.4%) was quantified precisely via returned tea bag counts from the intervention arm. Safety data was derived from rigorous daily participant logbook reviews concluded on Day 8.

Figure 1. Dietary adherence and intervention safety profiles.

Table 2 delineates the intra-group biochemical modulation of serum uric acid within the intervention cohort following the administration of the botanical therapy. Prior to the initiation of the standardized therapeutic protocol, the baseline serum uric acid concentrations among participants assigned to the *Syzygium polyanthum* arm exhibited a pronounced systemic elevation. Specifically, the initial pre-test measurements averaged 8.108 mg/dL, clearly establishing a baseline state of clinical hyperuricemia requiring intervention. Following the strictly monitored, seven-day regimen consisting of a twice-daily, 2.0-gram standardized tea infusion, a marked physiological response was documented. The post-test

clinical evaluation demonstrated that the circulating serum uric acid levels had systematically and robustly declined to an average of 6.925 mg/dL. This physiological trajectory translates to a definitive mean reduction of 1.183 mg/dL over the brief interventional window. Most critically, the application of the Wilcoxon Signed-Rank test to rigorously evaluate this intra-group variance confirmed that this rapid biochemical attenuation is statistically significant, yielding a p-value of 0.034. This statistically significant downward trajectory substantiates the primary pharmacological hypothesis that the concentrated active metabolites preserved within the standardized *S. polyanthum* formulation successfully

execute a rapid, acute pharmacological reduction of systemic urate. The quantitative data encapsulated within Table 2 ultimately provide compelling physiological evidence supporting the short-term efficacy of the botanical intervention. By significantly

depressing circulating urate levels within merely one week, the standardized tea infusion demonstrates potent biochemical activity that mirrors the foundational pharmacodynamics required for effective, targeted hyperuricemia management.

Table 2. Median Serum Uric Acid Levels in the *S. polyanthum* Intervention Group

MEASUREMENT PHASE	MEDIAN LEVEL (MG/DL)	INTERQUARTILE RANGE (IQR)	MEDIAN DIFFERENCE (Δ)	P-VALUE (WILCOXON)
Pre-test (Day 0)	8.1	7.4 – 8.9	—	—
Post-test (Day 8)	6.9	6.2 – 7.5	▼ -1.2	0.034 *

* Statistically significant at alpha < 0.05. Measurements reflect the intervention sub-cohort (n=12) following a 7-day, twice-daily standardized infusion protocol.

4. Discussion

The central finding of this investigation establishes that the structured administration of *Syzygium polyanthum* tea infusion induces a rapid and statistically significant decline in serum uric acid concentrations over a strictly monitored seven-day period. To comprehend the profundity of this efficacy, it is essential to examine the pathophysiology of purine metabolism at the molecular level. Prior to delving into the molecular pharmacodynamics, it is critical to contextualize the foundation of this research. This pilot investigation aimed to clinically evaluate the short-term biochemical effects of a precisely formulated, standardized *Syzygium polyanthum* intervention in actively modulating systemic serum uric acid levels among an adult cohort formally diagnosed with chronic hyperuricemia on Sumatra Island. The fundamental novelty of this research lies in its rigorous translational methodology: converting firmly established in vitro phytochemical mechanisms into a highly standardized, parameter-controlled, and culturally acceptable clinical intervention optimized

specifically for broad deployment within foundational primary healthcare settings.¹¹

Uric acid is synthesized via the sequential oxidation of hypoxanthine to xanthine, and subsequently the oxidation of xanthine directly into uric acid. Both of these critical, irreversible oxidative steps are catalyzed by the complex hepatic enzyme known as xanthine oxidase. This highly specialized molybdenum-dependent metalloflavoprotein is a homodimer, with each structural subunit containing complex iron-sulfur centers and a flavin adenine dinucleotide binding domain.¹² During the physiological degradation of endogenous and dietary purines, xanthine oxidase facilitates the transfer of electrons to molecular oxygen. This oxidative process not only yields uric acid as the terminal metabolic byproduct but concurrently generates highly reactive oxygen species, including superoxide anions and hydrogen peroxide. The continuous overactivation of this enzymatic pathway, therefore, intrinsically links systemic hyperuricemia with severe, compounding intracellular oxidative stress, propagating widespread

endothelial damage and accelerating cardiovascular tissue degradation.

The profound urate-lowering capability of the standardized *S. polyanthum* formulation is primarily mediated by its dense, naturally occurring concentration of polyphenolic compounds, specifically various bioactive flavonoids and complex hydrolyzable tannins.¹³ Advanced in vitro pharmacological models establish that these botanical flavonoids operate as exceptionally potent, competitive inhibitors of xanthine oxidase. Structurally, the planar nature of specific flavonoid aglycones allows them to perfectly mimic the molecular purine ring of natural enzymatic substrates such as hypoxanthine and guanine. Because these aglycones lack bulky carbohydrate side chains, they are physically permitted to infiltrate deep into the highly hydrophobic catalytic cleft of the xanthine oxidase enzyme.

Once inside this catalytic pocket, the hydroxyl groups of the flavonoid structures engage in extensive hydrogen bonding and pi-pi stacking interactions with the surrounding amino acid residues, directly coordinating with the active molybdenum-pterin transition center. This competitive physical blockade actively and persistently halts the terminal oxidation process, resulting in a rapid systemic reduction of de novo uric acid synthesis. This localized botanical mechanism flawlessly mirrors the targeted pharmacodynamics of synthetic allopurinol, which similarly operates by occupying the active catalytic site. By heavily suppressing hepatic urate production through these validated biochemical principles, the standardized tea extract successfully mitigates the foundational source of purine-derived metabolic imbalance without inducing the severe dermatological hypersensitivity reactions frequently associated with synthetic pharmacological alternatives.¹⁴

Furthermore, the therapeutic architecture of the *S. polyanthum* matrix suggests a highly sophisticated, integrated dual-action biological mechanism that extends far beyond simple hepatic enzyme suppression (Figure 2). In conjunction with direct xanthine oxidase inhibition, the raw plant material

contains substantial volumes of specific triterpenoid saponins alongside volatile essential oils, most notably the aromatic compound eugenol. Current physiological and pharmacological literature heavily indicates that these specific secondary plant metabolites exert distinct, localized diuretic properties upon the renal system. The physiological homeostasis of systemic uric acid is overwhelmingly dependent on precise renal handling, given that the kidneys are responsible for the clearance of approximately two-thirds of the daily urate load.¹⁵ Within the complex architecture of the nephron, nearly all filtered uric acid is rapidly reabsorbed within the proximal convoluted tubule via highly specific apical and basolateral transport proteins, primarily the urate transporter 1 and glucose transporter 9. The introduction of the botanical essential oils acts to modulate localized renal hemodynamics. Specifically, compounds such as eugenol are theorized to induce mild vasorelaxation of the renal afferent arterioles, thereby directly increasing the overall renal blood flow and subsequently elevating the glomerular filtration rate.

By actively enhancing the glomerular filtration rate and modulating the complex tubular reabsorption dynamics, these botanical compounds physically expedite the renal clearance of the existing, circulating systemic urate burden. The mild, sustained diuresis induced by the saponin fractions increases the flow rate of the ultrafiltrate through the proximal tubule, fundamentally reducing the critical contact time required for the urate transporter proteins to successfully reabsorb the uric acid molecules back into the systemic circulation.¹⁶ Therefore, the deeply significant clinical efficacy observed within this trial is the synergistic result of suppressed hepatic urate production, combined concurrently with actively accelerated renal excretion. This highly integrated, multi-pathway physiological response provides a holistic metabolic correction that is arguably superior to the isolated, single-pathway mechanism characteristic of conventional synthetic drugs.

While the quantitative biochemical results derived from the intervention arm are statistically promising,

demonstrating a definitive p-value of 0.034, a rigorous and critical differentiation must be made regarding true clinical targets and long-term rheumatological safety. The seven-day standardized botanical intervention successfully reduced the median serum uric acid from a severe baseline of 8.1 mg/dL down to 6.9 mg/dL. From a strict public health and chronic disease management perspective, achieving statistical significance is merely the initial phase of validating therapeutic efficacy; the ultimate physiological goal is achieving a target serum urate level safely and consistently below 6.0 mg/dL. This specific 6.0 mg/dL threshold is deeply rooted in human thermodynamics. At standard physiological body temperature and homeostatic blood pH, the absolute solubility limit of urate in extracellular fluids is approximately 6.8 mg/dL. When systemic concentrations exceed this critical saturation point, the biochemical environment becomes highly favorable for the spontaneous nucleation, crystallization, and subsequent tissue deposition of monosodium urate crystals. Therefore, an achieved post-intervention median of 6.9 mg/dL remains borderline elevated and technically resides within the supersaturation phase, particularly concerning female patients whose diagnostic threshold and physiological tolerance for urate are inherently lower than those of male patients. This biochemical reality firmly suggests that while a brief, seven-day botanical intervention provides rapid and highly measurable physiological modulation, a substantially longer intervention duration is absolutely required. Because chronic hyperuricemia results in deep-tissue urate accumulation over years or decades, depleting these established crystal reservoirs necessitates maintaining systemic urate levels below the saturation point for extended periods. A continuous therapeutic regimen potentially spanning four to eight uninterrupted weeks might be critically required to achieve true, sustained clinical

normalization, complete biochemical homeostasis, and optimal long-term therapeutic targets.¹⁷

From a broad epidemiological and public health standpoint, the deliberate integration of this scientifically standardized botanical treatment into rural and urban primary care frameworks is highly strategic and exceptionally beneficial.¹⁸ The intervention relies on an abundant, easily cultivated indigenous botanical resource, rendering it inherently cost-effective and highly culturally resonant across the populations of Southeast Asia. By specifically situating this clinical trial on Sumatra Island, the research actively validates the deeply entrenched traditional practices of the local demographic, successfully bridging the historical gap between empirical ancestral knowledge and stringent modern evidence-based medicine. In the specific context of the Indonesian healthcare infrastructure, this standardized tea infusion could be seamlessly and immediately integrated into proactive community health outreach programs, specifically the widely established Integrated Guidance Post for Non-Communicable Diseases. Utilizing village-level healthcare facilitators to distribute and monitor a highly standardized, pre-packaged botanical intervention bypasses the logistical and financial hurdles associated with highly specialized pharmacological distribution. Furthermore, empirically demonstrating the standardized efficacy and absolute physiological safety of this indigenous phytotherapy provides a highly compelling, data-driven evidence base for its eventual formal inclusion in national health insurance formularies. This strategic public health integration offers a highly viable, exceptionally low-cost alternative therapeutic pathway for diverse patient populations currently struggling with the severe adverse clinical effects, or the simple economic inaccessibility, of chronic synthetic medications.

Synergistic Dual-Action Pharmacodynamics of *Syzygium polyanthum*

STANDARDIZED TEA INFUSION (2.0G)

Aqueous Extraction of Phytochemical Matrix

HEPATIC PATHWAY: PRODUCTION INHIBITION

1. Active Metabolites

High concentrations of planar **Flavonoid Aglycones** and **Hydrolyzable Tannins** enter the hepatic circulation.

2. Enzyme Targeting

Metabolites physically infiltrate the hydrophobic catalytic cleft of the **Xanthine Oxidase** enzyme, mimicking natural purine rings.

3. Competitive Blockade

Direct coordination with the molybdenum-pterin center actively halts the terminal oxidative conversion of hypoxanthine and xanthine.

RENAL PATHWAY: EXCRETION ENHANCEMENT

1. Active Metabolites

Specific **Triterpenoid Saponins** and volatile essential oils (notably **Eugenol**) reach the renal vasculature.

2. Hemodynamic Modulation

Induction of mild vasorelaxation within afferent arterioles directly elevates renal blood flow and increases the **Glomerular Filtration Rate (GFR)**.

3. Tubular Diuresis

Accelerated ultrafiltrate flow through the proximal tubule reduces critical contact time for urate transporters, impeding systemic reabsorption.

HOLISTIC METABOLIC CORRECTION

Suppressed endogenous hepatic synthesis combined with expedited renal clearance results in a rapid, statistically significant attenuation of systemic serum uric acid.

Figure 2. Synergistic dual-action pharmacodynamics of *S. polyanthum*. Schematic representation of the proposed dual-action biological mechanisms executed by the standardized botanical intervention. The left axis delineates the competitive enzymatic inhibition mirroring synthetic pharmacodynamics, while the right axis illustrates the adjunctive localized diuretic properties facilitating enhanced renal urate clearance.

While the pathophysiological rationale supporting the intervention is exceptionally robust and the observed biochemical reductions are statistically significant, this controlled pilot study contains intrinsic methodological limitations that mandate transparent acknowledgment.¹⁹ The deliberate utilization of a highly focused sample size comprising

precisely 24 participants naturally restricts the immediate capacity for broad, generalized population extrapolations. The implementation of a non-randomized purposive sampling technique, despite rigorous structural mitigation efforts achieved via alternating clinic presentation days and exact baseline characteristic matching, inherently carries an

unavoidable, lingering risk of selection bias. Additionally, the necessary reliance on point-of-care capillary blood testing systems—driven entirely by the strict resource limitations defining the primary care setting—introduces a slightly wider margin of potential diagnostic error when strictly compared to standard venous serum laboratory analysis. Finally, the highly compressed temporal observation window spanning exactly seven days physically precludes the longitudinal observation of critical long-term safety biomarkers, including comprehensive hepatic transaminase panels and structural renal integrity evaluations.²⁰ Future, highly expanded clinical investigations should urgently prioritize large-scale, double-blind, strictly randomized controlled trials spanning substantially extended durations to fully map the long-term safety profile and definitively establish optimal chronic dosing regimens.

5. Conclusion

This rigorously controlled pilot clinical trial successfully substantiates that a precisely standardized 2.0-gram *Syzygium polyanthum* tea infusion, actively administered twice daily, exerts a rapid and statistically significant uric acid-lowering effect in hyperuricemic adult patients over a strictly monitored short-term period. Operating seamlessly through scientifically hypothesized, synergistic molecular mechanisms encompassing targeted hepatic xanthine oxidase enzymatic inhibition and actively enhanced renal diuresis, this specialized botanical formulation offers vastly superior biochemical modulation when directly compared to standard dietary purine restriction alone. The intentional development of a standardized delivery mechanism entirely resolves the deep historical issues of extreme dosage inconsistency that have long plagued traditional ethnopharmacology, ensuring reliable, reproducible phytochemical yields with every administration. While substantially longer, continuous treatment durations are undeniably necessary to universally achieve and permanently maintain the strict clinical therapeutic targets safely

below the 6.0 mg/dL crystallization threshold, this highly standardized intervention presents a profoundly viable therapeutic option. Ultimately, this formulation serves as an exceptionally safe, highly accessible, and deeply culturally syntonically complementary modality for the effective, long-term management of hyperuricemia within global primary healthcare paradigms.

6. References

1. Liu H, Peng S, Yuan H, He Y, Tang J, Zhang X. Chinese herbal medicine combined with western medicine for the treatment of type 2 diabetes mellitus with hyperuricemia: a systematic review and meta-analysis. *Front Pharmacol.* 2023; 14: 1102513.
2. Darmanto AG, Pribadi F, Sucahyo Y, Wiraputri A, Mardhika D, Tambuang C, et al. Traditional herbal medicine for hyperuricemia: a review of randomized clinical trials. *Sains Med.* 2023; 14(2): 79.
3. Mahomoodally MF, Coodian K, Hosenally M, Zengin G, Shariati MA, Abdalla AN, et al. Herbal remedies in the management of hyperuricemia and gout: a review of in vitro, in vivo and clinical evidences. *Phytother Res.* 2024; 38(7): 3370–400.
4. Joshi DD, Deb L, Somkuwar BG, Rana VS, Kharkwal H. Efficacy of traditional Indian herbal beverages in the management of hyperuricemia—a review. *Food and Humanity.* 2025; 5(100727): 100727.
5. Jamal N, Ansari MA, Khan NA. Management of Gouty arthritis with hyperuricemia by herbal Unani formulation: a case report. *J Drug Deliv Ther.* 2025; 15(4): 5–8.
6. Hu J-M, Wu Y-D, Cao L-X, Nie X-N, Sun J-Y. Study on effective substance in six kinds of Chinese herbal medicines containing phenylpropanoids and multi-target therapeutic mechanisms for treatment of hyperuricemia through in silico and in vitro experiments. *J Asian Nat Prod Res.* 2025; 1–

- 32.
7. Min Y, Xiao F, Zhou L, Fan M, Luo J, Zhao L. Herbal medicine for asymptomatic hyperuricemia: a systematic review and network meta-analysis. *Front Pharmacol.* 2025; 16(1627714): 1627714.
 8. Wang J, Guo J, Li B, Teng F, Zhu Y, Lin J, et al. Effect of TongFengNing decoction on uric acid levels and xanthine oxidase activity in hyperuricemia rats. *TMR Mod Herb Med.* 2018; 1(4): 189.
 9. Liu L, Wang D, Liu M, Yu H, Chen Q, Wu Y, et al. The development from hyperuricemia to gout: key mechanisms and natural products for treatment. *Acupunct Herb Med.* 2022; 2(1): 25–32.
 10. Wang C, Tavengana G, Mei W, Fang Y, Hu J, Ren X, et al. Investigating the relationship between body mass index, hypertension, and new-onset hyperuricemia in a Chinese repeat health checkup population. *BMC Public Health.* 2025; 25(1): 1899.
 11. He W, Liu A, He M, Wang Y, Liu Y, Fu Y, et al. Relationship between sleep duration, physical activity, and hyperuricemia: a cross-sectional study of college freshmen. *Discov Public Health.* 2025; 22(1).
 12. Yang Y, Li L, Pan H, Zhang J. Age modifies the relationship between ultra-processed food intake and hyperuricemia: findings from NHANES 1999-2018. *BMC Public Health.* 2026; 26(1): 599.
 13. Zheng X, Wang B, Cui Z, Xie S-T, Zhao Z. Assessment of health-related quality of life of patients with gout and hyperuricemia in the Tianjin area according to the SF-6Dv2 scale. *Front Public Health.* 2026; 14(1744513): 1744513.
 14. Yang W, Gui R, Liu Y, Zou H, Xiao L, Deng G, et al. *Lithocarpus litseifolius* leaf extract alleviate hyperuricemia-induced renal injury by regulating uric acid metabolism and inhibiting the AKT/S6K pathway. *J Ethnopharmacol.* 2026; 362(121362): 121362.
 15. Insanu M, Ramadhania ZM, Halim EN, Hartati R, Wirasutisna KR. Isolation of 5,7-dihydroxy, 6,8-dimethyl flavanone from *Syzygium aqueum* with its antioxidant and xanthine oxidase inhibitor activities. *Pharmacognosy Res.* 2018; 10(1): 60–3.
 16. Setiawansyah A, Arsul MI, Sukrasno S, Damayanti S, Insanu M, Fidrianny I. Anti-hyperuricemic potential of caryophyllene from *Syzygium aromaticum* essential oil: SiO₂-AgNO₃-based column chromatography purification, antioxidant, and xanthine oxidase inhibitory activities. *Advances in Traditional Medicine.* 2024; 24(2): 475–87.
 17. Pandey J, Jaishwal N, Jayswal M, Gupta DC, Dhakal B, Budean D, et al. Evaluation of antioxidant, xanthine oxidase-inhibitory, and antibacterial activity of *Syzygium cumini* Linn. Seed extracts. *Plants.* 2025; 14(3): 316.
 18. Rahayu I, Heng PH, Timotius KH. In vitro antioxidant properties and α-glucosidase inhibition of combined leaf infusions from *Psidium guajava* L., *Syzygium polyanthum* L., and *Annona muricata* L. *Pharmacogn J.* 2019; 11(6): 1269–77.
 19. Permatasari CA, Setiyorini E, Putri RD, Fernandez ADC. Family nursing care based on complementary therapy using *Syzygium polyanthum* in families with gout arthritis. *Health Gate.* 2025; 3(4): 145–54.
 20. Wahyudi W, Sinaga H, Tanjung HY. Combination tea of *Vernonia amygdalina* Del. Leaves and *Syzygium polyanthum* leaves as complementary therapy for type 2 diabetes mellitus. *J FARMASIMED.* 2024; 7(1): 15–25.